Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - A randomized, placebo-controlled, pilot study

Journal of Crohn's and Colitis

Volumn 8, Issue 3, 2014, Pages 208-214

  Singla, Vikas ^a   Pratap Mouli, Venigalla ^a   Garg, Sushil Kumar ^a   Rai, Tarun ^a   Choudhury, Bikash Narayan ^a   Verma, Prashant ^a   Deb, Rachana ^a   Tiwari, Veena ^a   Rohatgi, Sarika ^a   Dhingra, Rajan ^a   Kedia, Saurabh ^a   Sharma, Piyush Kumar ^a   Makharia, Govind ^a   Ahuja, Vineet ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Curcumin; NCB 02; Ulcerative colitis

Indexed keywords

CURCUMIN; NCB-02; ULCERATIVE COLITIS;

ADMINISTRATION, RECTAL; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; CURCUMIN; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; ENEMA; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84894279232     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.08.006     Document Type: Article

References (24)

1. Sartor R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008, 134:577-594.
2. Elson C.O., Sartor R.B., Tennyson G.S., Riddell R.H. Experimental models of inflammatory bowel disease. Gastroenterology 1995, 109:1344-1367.
3. Rogler G., Andus T. Cytokines in inflammatory bowel disease. World J Surg 1998, 22:382-389.
4. Schreiber S., Nikolaus S., Hampe J. Activation of nuclear factor êB in inflammatory bowel disease. Gut 1998, 42:477-484.
5. Ardite E., Panes J., Miranda M., Salas A., Elizalde J.I., Sans M., et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol 1998, 124:431-433.
6. Kaiser G.C., Yan F., Polk D.B. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology 1999, 116:602-609.
7. Baumgart D.C., Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007, 369:1641-1657.
8. Sugimoto K., Hanai H., Tozawa K., Aoshi T., Uchijima M., Nagata T., et al. Curcumin prevents and ameliorates trinitrobenzene surfonic acid induced colitis in mice. Gastroenterology 2002, 123:1912-1922.
9. Deguchi Y., Andoh A., Inatomi O., Yagi Y., Bamba S., Araki Y., et al. Curcumin prevents the development of dextran sulfate Sodium (DSS)-induced experimental colitis. Dig Dis Sci 2007, 52:2993-2998.
10. Arafa H.M., Hemeida R.A., El-Bahrawy A.I., Hamada F.M. Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem Toxicol 2009, 47:1311-1317.
11. Jagetia G.C., Aggarwal B.B. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007, 27:19-35.
12. Ukil A., Maity S., Karmakar S., Datta N., Vedasiromoni J.R., Das P.K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003, 139:209-218.
13. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., et al. Curcumin blocks cytokine-mediated NF-kB activation and pro-inflammatory gene expression by inhibiting inhibitory factor I-kB kinase activity. J Immunol 1999, 163:3474-3483.
14. Camacho-Barquero L., Villegas I., Sánchez-Calvo J.M., Talero E., Sánchez-Fidalgo S., Motilva V., et al. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int Immunopharmacol 2007, 7:333-342.
15. Larmonier C.B., Midura-Kiela M.T., Ramalingam R., Laubitz D., Janikashvili N., Larmonier N., et al. Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. Inflamm Bowel Dis 2011, 17:503-515.
16. Ung V.Y., Foshaug R.R., MacFarlane S.M., Churchill T.A., Doyle J.S., Sydora B.C., et al. Oral administration of curcumin emulsified in carboxymethyl cellulose has a potent anti-inflammatory effect in the IL-10 gene-deficient mouse model of IBD. Dig Dis Sci 2010, 55:1272-1277.
17. Salh B., Assi K., Templeman V., Parhar K., Owen D., Gomez-Munoz A., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 2003, 285:G235-G243.
18. Holt P.R., Katz S., Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 2005, 50:291-293.
19. Hanai H., Iida T., Takeuchi K., Watanabe F., Maruyama Y., Andoh A., et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006, 4:1502-1506.
20. Sutherland L.R., Martin F., Greer S., Robinson M., Greenberger N., Saibil F., et al. 5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987, 92:1894-1898.
21. Wahl C., Liptay S., Adler G., Schmid R.M. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998, 101:1163-1174.
22. Kumar S., Ahuja V., Sankar M.J., Kumar A., Moss A.C. Curcumin for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012, 10:CD008424.
23. Rao C.V., Simi B., Reddy B.S. Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis 1993, 14:2219-2225.
24. Pereira M.A., Grubbs C.J., Barnes L.H., Li H., Olson G.R., Eto I., et al. Effects of the phytochemicals, curcumin and quercetin, upon azoxymethane induced colon cancer and 7,12-dimethylbenz[a]anthracene-induced mammary cancer in rats. Carcinogenesis 1996, 17:1305-1311.